Holen Sie sich die Stockscreener-App
6.53
3.65%
0.23
Vorhandelsmarkt:
6.26
-0.27
-4.13%
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Sagimet Biosciences (SGMT) director receives 39,567 stock options grant - Stock Titan
Sagimet Biosciences (SGMT) director receives stock option grant for 39,567 shares - Stock Titan
Director at Sagimet Biosciences (NASDAQ: SGMT) receives 39,567 stock options - Stock Titan
Sagimet Biosciences (SGMT) director receives 39,567 stock options at $6.48 - Stock Titan
Sagimet Biosciences (SGMT) grants director Kemble George 39,567 stock options - Stock Titan
Director Anne Phillips receives 39,567 Sagimet (SGMT) stock options at $6.48 strike - Stock Titan
Sagimet Biosciences Announces Board Changes and Director Elections - TipRanks
Tim Walbert resigns from Sagimet's board - TradingView
Sagimet Biosciences (SGMT) director resigns as shareholders elect Board, ratify KPMG - Stock Titan
Sagimet Biosciences Inc. Announces Resignation of Tim Walbert as Member of the Board of Directors, Effective as of June 12, 2026 - marketscreener.com
Certain Restricted Stock Units of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2026. - marketscreener.com
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher - MSN
Sagimet Biosciences Grants New Performance-Based Executive Equity Awards - TipRanks
[8-K] Sagimet Biosciences Inc. Reports Material Event - Stock Titan
Sagimet Biosciences (SGMT) Slides 1.99% as Stock Approaches Key Support ZoneCalendar Spread Trade - newsline.com
Sagimet Biosciences (SGMT) grants CEO options on 300,000 shares - Stock Titan
Sagimet (SGMT) CFO receives 50,000 options at $7.27 exercise price - Stock Titan
Sagimet Biosciences Inc. (SGMT) is a great momentum stock: Should you buy? - MSN
SGMT Stock Price, Quote & Chart | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH - Caledonian Record
Sagimet Biosciences Presents Two Posters At EASL 2026 On Denifanstat/Resmetirom Combination In MASH - marketscreener.com
Sagimet Biosciences (SGMT) Inches Higher as Stock Tests Key Resistance at $7.48Adaptive Moving Average - thelegaladvocate.com
Sagimet Biosciences (SGMT) Edges Higher as Clinical Momentum BuildsSentiment Divergence - thelegaladvocate.com
Sagimet Biosciences (SGMT) Gains 1.29% as Shares Test Key Resistance LevelPut Flow Alert - newsline.com
Sagimet Biosciences Inc. Q1 2026 Earnings: Narrowed Loss Beats Expectations as Clinical Pipeline Advances - newsline.com
SGMT Technical Analysis | Trend, Signals & Chart Patterns | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Why Are Analysts So Bullish on Sagimet Biosciences (SGMT) - Kavout
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade - MSN
SGMT Maintained by Citizens -- Price Target Lowered to $12 - GuruFocus
Citizens cuts Sagimet Biosciences stock price target on valuation By Investing.com - Investing.com Nigeria
Sagimet Biosciences Is Maintained at Market Outperform by Citizens - Moomoo
Citizens JMP Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Citizens cuts Sagimet Biosciences stock price target on valuation - Investing.com
Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results - MSN
Sagimet Biosciences (SGMT) price target increased by 15.00% to 29.86 - MSN
Number of shareholders of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Sagimet Biosciences (SGMT) CMO receives 264,759 stock options at $6.44 strike - Stock Titan
Sagimet Biosciences (SGMT) files Form 3 identifying Chief Medical Officer Andreas Grauer - Stock Titan
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat (NASDAQ:SGMT) - Seeking Alpha
Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target - TipRanks
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - GlobeNewswire
Biotech Sagimet to give fireside chat at NASDAQ investor event - Stock Titan
Sagimet Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Sagimet Biosciences reports first quarter 2026 financial results and provides corporate updates - marketscreener.com
Sagimet Biosciences Reports First Quarter 2026 Financial Results And Provides Corporate Updates - TradingView
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):